Synta Pharmaceuticals Corp. (MDGL)

Number of records: 50
SEC FilingInsiderCompanyTrade DateTransactionSharesAvg. PriceTotal% HoldingsReturn
25-Jan-24 3:29 PM
View: 
Howarth Alex G.
Chief Financial Officer
Synta Pharmaceuticals Corp. (MDGL) 23-Jan-24Grant 4,803----34%
13.93K to 18.74K
25-Jan-24 3:24 PM
View: 
Sibold William John
President and CEO
Director
Synta Pharmaceuticals Corp. (MDGL) 23-Jan-24Grant 12,250----25%
50.0K to 62.25K
25-Jan-24 3:24 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 23-Jan-24Grant 3,639----25%
14.58K to 18.22K
25-Jan-24 5:54 PM
View: 
Taub Rebecca
Pres., R&D, and CMO
Director
Synta Pharmaceuticals Corp. (MDGL) 23-Jan-24Grant 5,786----< 1%
1.11M to 1.11M
25-Jan-24 5:50 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 23-Jan-24Grant 1,419----28%
5.12K to 6.54K
25-Jan-24 6:04 PM
View: 
Huntsman Carole
Chief Commercial Officer
Synta Pharmaceuticals Corp. (MDGL) 23-Jan-24Grant 3,639----46%
7.83K to 11.47K
18-Jan-24 1:52 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 16-Jan-24Payment of Exercise 949$243.92$231,480.00(6%)
15.53K to 14.58K
18-Jan-24 1:46 PM
View: 
Taub Rebecca
Pres., R&D, and CMO
Director
Synta Pharmaceuticals Corp. (MDGL) 16-Jan-24Payment of Exercise 1,546$243.92$377,100.00(< 1%)
1.11M to 1.11M
18-Jan-24 1:45 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 16-Jan-24Payment of Exercise 550$243.92$134,156.00(10%)
5.67K to 5.12K
18-Jan-24 1:39 PM
View: 
Howarth Alex G.
Chief Financial Officer
Synta Pharmaceuticals Corp. (MDGL) 16-Jan-24Payment of Exercise 1,067$243.92$260,263.00(7%)
15.0K to 13.93K
18-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 15-Dec-23Option Exercise 2,000$87.92$175,840.0035%
5.67K to 7.67K
18-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 15-Dec-23Option Sale 2,000$238.50$477,000.00(26%)
7.67K to 5.67K
18-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 14-Dec-23Private Option Sale 2,000$232.50$465,000.00(26%)
7.67K to 5.67K
14-Dec-23 6:10 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 14-Dec-23Purchase 20,633$228.32$4,710,890.00< 1%
3.75M to 3.77M
18-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 14-Dec-23Option Exercise 2,000$87.92$175,840.0035%
5.67K to 7.67K
(7%)
14-Dec-23 6:10 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 13-Dec-23Purchase 81,159$219.39$17,805,700.004%
2.06M to 2.14M
14-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 13-Dec-23Option Exercise 2,500$87.92$219,800.0044%
5.67K to 8.17K
14-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 13-Dec-23Option Sale 2,500$225.40$563,500.00(31%)
8.17K to 5.67K
14-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 12-Dec-23Option Exercise 1,300$87.92$114,296.0023%
5.67K to 6.97K
(7%)
14-Dec-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 12-Dec-23Private Option Sale 1,300$217.85$283,200.00(19%)
6.97K to 5.67K
14-Dec-23 6:09 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 12-Dec-23Purchase 34,578$218.31$7,548,620.002%
1.84M to 1.88M
11-Dec-23 7:25 PM
View: 
Craves Fred B
Director
Synta Pharmaceuticals Corp. (MDGL) 07-Dec-23Disposition (other) 1,556,590----(76%)
2.05M to 489.69K
06-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 05-Dec-23Option Exercise 1,000$87.09$87,090.006%
15.53K to 16.53K
06-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 05-Dec-23Option Sale 1,000$227.33$227,330.00(6%)
16.53K to 15.53K
06-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 04-Dec-23Private Option Sale 1,800$218.87$393,964.00(10%)
17.33K to 15.53K
06-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 04-Dec-23Option Exercise 1,800$81.16$146,090.0012%
15.53K to 17.33K
< 1%
01-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 30-Nov-23Option Exercise 3,000$73.75$221,250.0019%
15.53K to 18.53K
01-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 30-Nov-23Option Sale 3,000$204.58$613,730.00(16%)
18.53K to 15.53K
01-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 29-Nov-23Option Exercise 4,000$73.75$295,000.0026%
15.53K to 19.53K
11%
01-Dec-23 4:30 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 29-Nov-23Private Option Sale 4,000$199.19$796,750.00(20%)
19.53K to 15.53K
21-Nov-23 6:15 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 21-Nov-23Purchase 64,350$188.48$12,128,300.004%
1.78M to 1.84M
21-Nov-23 6:14 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 20-Nov-23Purchase 20,709$185.74$3,846,580.001%
1.76M to 1.78M
22-Nov-23 5:02 PM
View: 
Huntsman Carole
Chief Commercial Officer
Synta Pharmaceuticals Corp. (MDGL) 20-Nov-23Grant 7,834----100%
0 to 7.83K
21-Nov-23 6:14 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 17-Nov-23Purchase 46,370$174.70$8,100,700.003%
1.71M to 1.76M
15-Nov-23 5:13 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 15-Nov-23Purchase 15,199$161.97$2,461,720.00< 1%
1.7M to 1.71M
15-Nov-23 5:13 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 14-Nov-23Purchase 34,188$156.42$5,347,840.002%
1.66M to 1.7M
15-Nov-23 5:12 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 14-Nov-23Purchase 37,660$154.00$5,799,650.002%
1.62M to 1.66M
15-Nov-23 5:12 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 13-Nov-23Purchase 69,839$143.21$10,001,400.004%
1.55M to 1.62M
13-Sep-23 4:41 PM
View: 
Sibold William John
President and CEO
Director
Synta Pharmaceuticals Corp. (MDGL) 11-Sep-23Grant 50,000----100%
0 to 50.0K
20-Jun-23 4:10 PM
View: 
Baker Bros Advisors LLC
Director
Synta Pharmaceuticals Corp. (MDGL) 15-Jun-23Grant 9,584----< 1%
1.55M to 1.55M
02-Mar-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 01-Mar-23Option Exercise 5,000$87.92$439,600.0088%
5.67K to 10.67K
02-Mar-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 01-Mar-23Option Sale 5,000$274.42$1,372,080.00(47%)
10.67K to 5.67K
02-Mar-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 28-Feb-23Private Option Sale 5,000$272.07$1,360,360.00(47%)
10.67K to 5.67K
02-Mar-23 4:30 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 28-Feb-23Option Exercise 5,000$87.92$439,600.0088%
5.67K to 10.67K
(7%)
11-Dec-23 7:25 PM
View: 
Craves Fred B
Director
Synta Pharmaceuticals Corp. (MDGL) 30-Jan-23Gift 3,557----(< 1%)
2.05M to 2.05M
19-Jan-23 7:57 PM
View: 
Levy Richard S
Director
Synta Pharmaceuticals Corp. (MDGL) 17-Jan-23Option Exercise 22,489$103.02$2,316,840.00247%
9.1K to 31.59K
19-Jan-23 7:57 PM
View: 
Levy Richard S
Director
Synta Pharmaceuticals Corp. (MDGL) 17-Jan-23Planned Option Sale 22,489$293.15$6,592,690.00(71%)
31.59K to 9.1K
18-Jan-23 8:00 PM
View: 
Lynch Brian Joseph
SVP and General Counsel
Synta Pharmaceuticals Corp. (MDGL) 16-Jan-23Grant 15,001----2830%
0.53K to 15.53K
18-Jan-23 8:00 PM
View: 
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Synta Pharmaceuticals Corp. (MDGL) 16-Jan-23Grant 5,667----100%
0 to 5.67K
18-Jan-23 8:00 PM
View: 
Taub Rebecca
Pres., R&D, and CMO
Director
Synta Pharmaceuticals Corp. (MDGL) 16-Jan-23Grant 20,001----2%
1.09M to 1.11M